31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. (September 2015) - Toulmonde, M.